New Diagnostic Approach Combines DNA Testing With AI Analysis for Coronary Heart Disease Risk Assessment

Despite significant progress in medical science, heart disease continues to be a leading cause of death across the globe. Early diagnosis is key for implementing preventive actions, but current methods often entail high costs, exposure to harmful radiation and contrast agents, and extensive wait times, sometimes 4-6 weeks, for scheduling and receiving results from tests such as the echo stress exam. Now, a revolutionary test utilizes epigenetics, genetics, artificial intelligence, and machine learning to more accurately and cost-effectively detect early signs of cardiovascular disease.

Cardio Diagnostics Inc.’s (Chicago IL, USA) new test, PrecisionCHD, employs cutting-edge technology to offer sensitivity that's 75% higher than conventional methods, while also delivering results up to two-thirds faster. This ground-breaking development promises to transform heart disease detection and treatment for the health-conscious generation. PrecisionCHD only requires a single blood sample, which can be collected at a doctor's office or at home using a lancet. This novel test harnesses the power of epigenetics and genetics in conjunction with artificial intelligence, offering unprecedented accuracy and speed in detecting coronary heart disease. Furthermore, the six epigenetic indices that are the foundation of PrecisionCHD enable physicians to use Cardio Diagnostics' Actionable Clinical Information platform to tailor treatment to the patient's unique risk profile. PrecisionCHD eliminates guesswork concerning the causes of heart disease, providing a clear, comprehensible picture of the underlying biology.

PrecisionCHD outperforms traditional methods in terms of cost-effectiveness and accuracy, with 75% higher sensitivity. This means it can identify diseases at earlier stages and lower thresholds than ever before. This innovative approach also circumvents the need for expensive echo stress tests, as it can provide reliable results up to two-thirds faster, making it ideal for individuals requiring prompt, accurate diagnosis. In addition to being faster and more accurate, PrecisionCHD offers scalable heart health solutions that can be deployed globally. Its accuracy isn't compromised by geographical location or access to healthcare, making it a viable response to the growing demand for cardiovascular solutions in today's world. This scalability ensures its suitability for both developing nations with limited resources and developed countries where healthcare access can be costly and time-consuming.

“The launch of PrecisionCHD represents a leap forward in cardiovascular medicine. I’m beyond thrilled that we’re able to make the promise of precision cardiovascular medicine a reality,” said Robert Philibert, MD Ph.D., the company’s Chief Medical Officer and Co-Founder. “Clinicians seeking to assess coronary heart disease status in their patients no longer have to worry about their ability to obtain an exercise stress test or angiogram. Now, clinicians can have a blood sample drawn in their office or a kit sent to their patient’s home for this highly sensitive test.”

Related Links:
Cardio Diagnostics Inc. 

Visit expo >

Gold Member

Troponin T QC

Troponin T Quality Control

Antipsychotic TDM AssaysSaladax Antipsychotic Assays

New

Automated Nucleic Acid Extractor

eLab

New

Quantitative Immunoassay Analyzer

AS050